Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Head and Neck Neoplasms

Interventions: Drug: BI 754111
Drug: [89Zr]Zr-BI 754111
Drug: BI 754091

First Posted Date: 2018-12-19

Last Posted Date: 2021-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT03780725

Locations: 🇳🇱
Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Phase 1

Withdrawn

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: BI 705564
Drug: Placebo

First Posted Date: 2018-12-11

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT03771885

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors

First Posted Date: 2018-12-05

Last Posted Date: 2022-02-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1502

Registration Number: NCT03764631

Locations: 🇸🇦
Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
🇸🇦
Shifa Hospital, Makkah, Saudi Arabia
🇸🇦
Prince Fahad bin Sultan hospital, Tabuk, Saudi Arabia

and more 18 locations

A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: TRADIANCE® Combination Tablets AP
Drug: TRADIANCE® Combination Tablets BP

First Posted Date: 2018-12-03

Last Posted Date: 2023-01-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1164

Registration Number: NCT03761797

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 1358894 Affects the Way the Body Breaks Down Midazolam

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894
Drug: Placebo
Drug: Midazolam

First Posted Date: 2018-11-27

Last Posted Date: 2025-04-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT03754959

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

Phase 2

Completed

Conditions: Crohn Disease

Interventions: Drug: Spesolimab
Drug: Placebo

First Posted Date: 2018-11-26

Last Posted Date: 2024-02-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT03752970

Locations: 🇦🇹
AKH - Medical University of Vienna, Wien, Austria
🇧🇪
UZ Leuven, Leuven, Belgium
🇩🇪
Universitätsklinikum Erlangen, Erlangen, Germany

and more 7 locations

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: BI 705564
Drug: Placebo

First Posted Date: 2018-11-20

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT03747926

Effectiveness of Triple Therapy in COPD

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)
Drug: Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)

First Posted Date: 2018-10-30

Last Posted Date: 2019-12-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8853

Registration Number: NCT03724877

Locations: 🇬🇧
Clinical Practice Research Datalink, London, United Kingdom

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 894416 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Itraconazole
Drug: BI 894416

First Posted Date: 2018-10-26

Last Posted Date: 2023-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT03722173

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase 4

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Other: Pulmonary rehabilitation program

First Posted Date: 2018-10-23

Last Posted Date: 2021-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 19

Registration Number: NCT03717012

Locations: 🇺🇸
The LaPorte County Institute for Clinical Research, Michigan City, Indiana, United States
🇺🇸
Temple University Hospital, Oaks, Pennsylvania, United States
🇺🇸
Metroplex Pul and Sleep Ctr, McKinney, Texas, United States

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy